SHR-A2009 + almonertinib

**SHR-A2009 + almonertinib** is a combination regimen under clinical investigation for advanced solid tumors, especially unresectable locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR mutations. SHR-A2009 is administered intravenously, while almonertinib is given orally as mesilate tablets. Almonertinib is a third-generation, orally available EGFR tyrosine kinase inhibitor (TKI) targeting EGFR sensitizing and T790M resistance mutations, approved in China for EGFR T790M mutation-positive NSCLC. Mechanistically, almonertinib inhibits EGFR signaling and can also reverse multidrug resistance by inhibiting ABCB1 (P-glycoprotein), thereby resensitizing cancer cells to cytotoxic drugs. The combination aims to leverage these mechanisms for enhanced antitumor efficacy and to overcome resistance in advanced cancer patients[2][3][4].

Brand names

Ameile

Other names

SHR-A2009 + Almonertinib Mesilate Tablets